Perampanel
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Idiopathic Generalized Epilepsy
Conditions
Idiopathic Generalized Epilepsy, Partial Onset Seizures, Generalised Tonic-Clonic Seizures
Trial Timeline
Jul 20, 2020 → Jan 12, 2023
NCT ID
NCT04252846About Perampanel
Perampanel is a pre-clinical stage product being developed by Eisai for Idiopathic Generalized Epilepsy. The current trial status is completed. This product is registered under clinical trial identifier NCT04252846. Target conditions include Idiopathic Generalized Epilepsy, Partial Onset Seizures, Generalised Tonic-Clonic Seizures.
What happened to similar drugs?
20 of 20 similar drugs in Idiopathic Generalized Epilepsy were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01871233 | Pre-clinical | Completed |
| NCT02307578 | Pre-clinical | Completed |
| NCT05533814 | Approved | Completed |
| NCT04252846 | Pre-clinical | Completed |
| NCT03836924 | Pre-clinical | Completed |
| NCT03424564 | Phase 1 | Completed |
| NCT03288129 | Approved | Completed |
| NCT02914314 | Phase 2 | Completed |
| NCT02849626 | Phase 3 | Completed |
| NCT02726074 | Approved | Completed |
| NCT04230044 | Pre-clinical | Completed |
| NCT04257604 | Pre-clinical | Completed |
| NCT02727101 | Approved | Terminated |
| NCT02427607 | Phase 3 | Completed |
| NCT02279485 | Phase 1 | Completed |
| NCT02033902 | Pre-clinical | Completed |
| NCT01527006 | Phase 2 | Completed |
| NCT00903786 | Phase 2 | Completed |
| NCT00735397 | Phase 3 | Completed |
| NCT00505622 | Phase 3 | Terminated |
Competing Products
20 competing products in Idiopathic Generalized Epilepsy